Prothena | PRTA - Capital Ordinário





Capital Ordinário Alterar Data
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 166.46M 855K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Amgen USD 540M 1000K 2026-03
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Exelixis USD 253.7M 8.78M 2026-03
Immunic USD 120.38M 21.73M 2025-12
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
MacroGenics USD 63.32M 60K 2025-12
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Prothena USD 53.83M 3K 2025-12
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03
Xoma USD 87K 1000 2024-06